BeiGene : FDA Accepts BLA For Tislelizumab In Esophageal Squamous Cell Carcinoma
13/9 07:48
(RTTNews) - BeiGene Ltd. (BGNE) said Monday that the U.S. Food and Drug Administration accepted for review a Biologics License Application or BLA for its anti-PD-1 antibody tislelizumab as a treatment for patients with unresectable recurrent locally advanced or metastatic esophag...